spacer
home > epc > spring 2009 > the laws of attraction
PUBLICATIONS
European Pharmaceutical Contractor

The Laws of Attraction

The most challenging bottleneck for nearly every clinical trial is the recruitment of the intended number of patients within the planned timeframe. The selection of the best study sites is therefore of crucial importance to the success of a clinical trial. In order to find a suitable site, it is necessary to understand the motivation to participate. These motivations can include:

  • Scientific interest in a new therapy option: this is a very frequent reason to participate in clinical trials, especially for university hospitals and other scientific oriented organisations
  • The possibility to offer clinical studies to the patients: centres for specific indications and severe diseases are expected to be able to provide the option to participate in clinical trials to their patients
  • Strong relation to the sponsor: if an investigator has already been involved in early stages of the clinical development, they are certainly likely to be interested in participating in later phase clinical studies
  • Financial interests: especially for clinical studies with substances that are not in the frontline of scientific interest, the fee for the treatment of patients within a study may be a motivator for participation in a clinical trial

Good sites combine as many of the above-mentioned motivations as possible.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Michael Sigmund is Managing Director of SSS International Clinical Research, which provides CRO services to the pharmaceutical and biotech industry. Michael has about 20 years’ experience in the field of clinical research. After studying veterinary medicine, he received his DVM in 1988 from the University of Munich. He then joined the pharmaceutical industry and held several positions within biotech and contract research companies. Michael has ample experience in setting up and running clinical trials in European countries. His main interest lies in steamlining information concerning clinical trials to allow easy and effective access to relevant status information for all  parties involved. Michael helped to develop SSS’s professional web-based study information system (SIS).

spacer
Michael Sigmund
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement